Having shown that HSVGM-CSF-treated melanoma cells can be used as an “antigen load” for iDCs to prime the generation of CTLs (Figure 1F), we went on to examine the consequences of HDAC inhibition for CTL priming. The gene discussed is HDAC9; the disease is melanoma.